Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

UK hospitals are seeing an increase in COVID-19 activity as the SARS-CoV-2 XFG variant, dubbed “American Covid” or “Stratus,” circulates in the country.

According to the latest data from the UK Health Security Agency (UKHSA), COVID positivity in hospital settings increased from 5.9% to 7.0%. The weekly hospital admission rate also rose from 0.81 to 1.20 per 100,000, an increase of about 48%.

London recorded the highest increase among regions, with its COVID hospital admission rate rising by 79%.

More than half of the sequenced positive samples were reported to be XFG. Among people aged over 85, hospital admission rates increased from 7.08 to 12.43 per 100,000.

However, the true number of infections could be higher because fewer people are testing for COVID-19 than during the pandemic.

Also read: Flu 2026: Symptoms To Watch For As New Season Begins

What Is the XFG Variant?

XFG is a recombinant SARS-CoV-2 variant formed from Omicron subvariants LF.7 and LP.8.1.2. The WHO records the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.

The variant has since been detected in multiple countries and remains among the SARS-CoV-2 variants being monitored by WHO.

What Are the Symptoms of XFG?

COVID symptoms can vary between individuals. Reported symptoms associated with the current circulation of XFG include:

• Cough

• Fever

• Sore throat

• Headache

• Runny nose

• Fatigue

Some people may also experience muscle and joint aches, gastrointestinal symptoms as well as eye or chest infections, while others may have no symptoms.

London GP Dr Renée Hoenderkamp has highlighted symptoms including sore throat, headache, runny nose, fatigue and flu-like aches, Daily Mail reported.

Read More: WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids

Does XFG Cause More Severe Disease?

There is currently no evidence that the variants circulating in the UK are causing more severe disease.

“There is no evidence that variants currently circulating in the UK are causing more severe disease,” Dr Siggins said. “However, COVID can still cause serious illness in those at greatest risk.”

The latest available figures cited in reports recorded seven deaths involving COVID in England in the week ending August 28, compared with six the previous week.

Older adults and people with underlying conditions remain more vulnerable to severe COVID.

How Worried Should We Be?

The current increase is not comparable with the waves seen during the height of the COVID pandemic. UKHSA classifies the current hospital admission rate as being at a baseline level.

“COVID is increasing, but from a low level, which is not unexpected at this time of year,” said Dr Matthew Siggins, lecturer in immunity and infection biology at the University of Surrey, according to reports.

WHO has assessed the additional public health risk posed by XFG as low at the global level. Current evidence does not indicate that XFG causes more severe illness or deaths than other circulating variants.

How Can You Protect Yourself?

People who develop a high temperature or feel particularly unwell should stay home and avoid contact with others while they recover.

People eligible for the autumn COVID vaccination are advised to get vaccinated to maintain protection against serious illness.

Most people have some immunity from previous infection, vaccination or both. However, immunity may decline over time and does not always prevent infection. Protection against severe disease is generally stronger.

WHO has said currently approved COVID vaccines are expected to continue providing protection against symptomatic and severe disease from XFG.

Robotic technology is set to become an accelerating tool across every specialty of medicine, covering diagnostics, treatment and therapy in India, Union Minister of State (Independent Charge) for Science & Technology Dr. Jitendra Singh said.

Speaking at the inaugural session of the International Conference of the Society of Robotic Surgery in New Delhi, Singh said robotics should not be viewed as technology limited to surgery but as a tool that could increasingly be used across different branches of medicine.

“It’s a tool. It will happen everywhere,” he said, adding that the future could see the emergence of robotic medicine, robotic endocrinology and robotic cardiology, just as AI is finding applications across medical specialties.

Robotics, AI and Precision Medicine

Singh said robotics, artificial intelligence (AI) and nanoscience could create a larger ecosystem for precision health delivery and precision medicine.

Emerging technologies, he said, could enable increasingly personalized healthcare based on an individual's genetic profile, environmental conditions, lifestyle and dietary patterns.

He said the next phase of medicine could see greater use of genetically driven diagnostics alongside advances in quantum technologies, nanomedicine, AI and robotics.

Gene Sequencing for Every Newborn

Singh also expressed a desire to launch gene sequencing for every newborn. Referring to the Genome India Program, he said 10,000 individuals have already been sequenced and that AI and robotics could support detailed genetic sequencing across India's population of 1.4 billion.

He also highlighted the potential of tele-robotics, sharing his experience of performing an ultrasound on a person located 10,000 kilometers away in Antarctica.

How Robotics Is Changing Surgery

The shift toward robotic medicine is already visible in surgery. AIIMS experts recently explained how robotic technology is changing gallbladder surgery, building on the transition from open surgery to laparoscopy and now robotic-assisted procedures.

Professor Hemanga K Bhattacharjee, Department of Surgical Disciplines, AIIMS New Delhi, said inflammation, adhesions, scarring and unexpected anatomy can make gallbladder surgery difficult.

“What the surgeon encounters once the procedure begins can be very different from what was expected. In such situations, robotic-assisted surgery can be an ideal option, as the enhanced visualization and instrument control can help the surgeon navigate difficult anatomy with greater precision,” Bhattacharjee said.

The AIIMS Department of Surgical Disciplines uses the da Vinci robotic system, which provides a high-definition 3D view and wristed instruments for controlled movements. The department has performed more than 1,500 robot-assisted surgeries across specialties, according to hospital authorities.

Will Robotics Replace Laparoscopy?

Dr. Sunil Chumber, Head of the Department of Surgical Disciplines at AIIMS, Delhi, has worked through the evolution from open surgery and mini-laparotomy to laparoscopy and robotic-assisted surgery.

He described robotic-assisted surgery as “a significant step forward” and said he considers it “a superior surgical platform” based on his experience.

“My expectation is that, eventually, gallbladder surgery will be performed robotically and conventional laparoscopy will be phased out,” Chumber said.

“Every generation of surgery builds on what came before it. Laparoscopy was a major advancement in its time, but having worked with robotic-assisted surgery, I believe robotics is the next step in that evolution.”

TikTok star Brooke Eby, who chronicled her life with amyotrophic lateral sclerosis (ALS), through candid, humorous and deeply personal videos, has died at 37.

Eby was diagnosed with ALS, also known as Lou Gehrig’s disease, in 2022 at age 33. ALS is a progressive neurodegenerative disease that damages the nerve cells responsible for voluntary muscle movement.

Brooke Eby Made ALS Personal

Eby became known for sharing the realities of living with ALS on social media. Her videos combined humor with candid accounts of how the disease affected her mobility, breathing, speech and daily life.

The ALS Network described her as an “extraordinary advocate, storyteller, community builder and friend” whose honesty and humor helped change how people understood ALS.

“Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another,” said Sheri Strahl, president and CEO of the ALS Network.

Eby also used her platform to challenge the perception that ALS mainly affects older men.

“I didn’t choose ALS, but I did choose to get loud, and be irreverent about it,” Eby said after receiving an award from the ALS Network for her advocacy.

Also read: New RNA Therapy For ALS, The Disease Stephen Hawking Had: Patient With Rare Motor Neuron Disease Improves

She Documented Her ALS Progression

Eby regularly updated followers as her condition progressed.

In June 2025, she said her breathing capacity had declined significantly over six months. She also shared that she had undergone a procedure to have a feeding tube placed in her stomach.

By January 2026, Eby said she had begun experiencing bulbar symptoms, which can affect speech and swallowing. She reported trouble swallowing, speech disturbances and excess saliva.

In September 2026, she shared that her speech had deteriorated rapidly.

“In the last few weeks, people just can’t understand me at all,” she said, explaining that speaking had also begun requiring careful positioning of her body.

Eby Wanted People To Understand ALS Can Affect Anyone

In a PEOPLE essay, Eby wrote that she wanted people to understand that ALS does not discriminate by age, gender or demographic.

“I have ALS at a relatable age. Personally, I always associated this disease with older men,” she wrote. “But I could be someone’s daughter, sister, mom, girlfriend, wife.”

While much of her content was comedic, Eby also educated her audience about ALS, including how symptoms can vary and how the disease progresses.

Read More: Stanford Scientists Say The Human Brain May Be Two Separate Organs: How It Could Affect ALS & SMA Research

What Is ALS?

ALS affects motor neurons in the brain and spinal cord that control voluntary muscle movement. As these nerve cells degenerate, people can develop muscle weakness, loss of movement, difficulty speaking and swallowing, and eventually breathing problems.

ALS can begin in the limbs or with speech and swallowing problems, known as bulbar-onset ALS.

There is currently no cure for ALS, although treatments can help manage symptoms, improve quality of life and extend survival.

ALS Symptoms

Symptoms vary but can include:

• Muscle weakness
• Muscle cramps and twitching
• Muscle atrophy
• Stiffness and spasticity
• Difficulty speaking or swallowing
• Breathing difficulties
• Changes in emotional expression

Some people with ALS also develop cognitive or behavioral changes.

Eby’s social media posts gave thousands of followers a candid look at how the disease could change everyday life, while helping raise awareness about a condition that is often associated with older adults.